| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 9.9 | 8.1 |
| Gross profit | 6.0 | 5.4 |
| Profit before tax | -3.2 | -6.1 |
| Net income | -3.2 | -6.1 |
| EPS (diluted, $ a share) | $0.00 | $-0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +22.3% |
|---|---|
| Gross margin | 61.1% |
| Operating margin | -34.6% |
10-Q filed with the SEC, OTC: ZOMDF. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Zomedica Corp.: key numbers
- Share price
- $0.0910Close, Nov 16
- Market cap
- $89.2M
- Shares outstanding
- 979.95MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Zomedica Corp.
All →Zomedica Financial Results
Zomedica reported record third-quarter revenue of $9.9 million, a 22% increase year-over-year, driven by strong demand for its PulseVet and Assisi therapeutic devices. The company significantly reduced its net loss by 48% and improved its cash burn by 32% to $3.2 million, marking its lowest third-quarter cash consumption on record.
- Term
- Q3 2026
“Zomedica delivered record third quarter revenue, continued year-over-year growth across our business, and made further progress in managing and improving upon operating costs and cash consumption.”
Larry Heaton, Chief Executive Officer of Zomedica
“Our results reflect sustained demand for our PulseVet® and Assisi® therapeutic device products, increasing adoption of our diagnostic offerings, and contributions from our Development Services segment.”
Larry Heaton, Chief Executive Officer of Zomedica